Article

Preventing recurrent urinary tract infections: Is a vaccine still feasible?

David Klumpp, PhD, and David T. Uehling, MD, explain the challenges inherent in developing a vaccine for UTI and discuss the status of current research.

Q. Please discuss how you became interested in a urinary tract infection vaccine.

Related Videos
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Patient talking with doctor | Image Credit: © bongkarn - stock.adobe.com
Shaya Taghechian, MD, answers a question during a video interview
doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Raveen Syan, MD, FPMRS, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Cassandra K. Kisby, MD, MS, answers a question during a Zoom video interview
Vikas Desai, MD, answers a question during a Zoom video interview
Related Content
Efficacy of sildenafil cream for FSAD maintained across patient subgroups
December 16th 2024

Efficacy of sildenafil cream for FSAD maintained across patient subgroups

Hannah Clarke
Age, race, and hormonal contraceptive use did not significantly impact the efficacy of sildenafil cream, 3.6%, in female sexual arousal disorder.
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff
In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.
Data show short-term benefit of certain hormonal treatments for GSM
September 10th 2024

Data show short-term benefit of certain hormonal treatments for GSM

Hannah Clarke
Data showed that vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers may provide benefit in the management of symptoms related to GSM.
Dr. Malik evaluates quality of Reddit content on recurrent UTIs
March 17th 2022

Dr. Malik evaluates quality of Reddit content on recurrent UTIs

Urology Times staff
“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.
Topical sildenafil cream found safe, tolerable in female sexual arousal disorder
August 27th 2024

Topical sildenafil cream found safe, tolerable in female sexual arousal disorder

Hannah Clarke
There were no differences in the number of treatment-related TEAEs in patients who received sildenafil cream vs patients who received placebo.
National Urogynecology Research Agenda: A Path Forward for Advancing the Treatment and Management of Pelvic Floor Disorders
March 25th 2024

National Urogynecology Research Agenda: A Path Forward for Advancing the Treatment and Management of Pelvic Floor Disorders

American Urogynecologic Society
Developed by the AUGS Scientific Committee and Research Agenda Writing Group
© 2024 MJH Life Sciences

All rights reserved.